NeOnc Technologies Appoints Ali Alabedin to Its Board of Directors
Key Highlights
- ➤Ali Alabedin appointed to NeOnc’s Board, effective October 9, 2026
- ➤Abu Dhabi grants IND authorization for NEO212 Phase 2 development
- ➤NEO212 completed Phase 1 dose escalation and advances toward Phase 2
- ➤Alabedin succeeds Dr. Steven L. Giannotta, who remains on Scientific Advisory Board
Expert Statements
Amir Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc
“Ali’s appointment strengthens our Board as we advance our clinical programs and build our presence in Abu Dhabi”
Amir Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc
“His experience in financial governance, regulatory engagement and international growth will help guide our next stage of development.”
Amir Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc
“We appreciate the Department of Health – Abu Dhabi’s support for our clinical expansion and share a commitment to bringing new treatment options to patients facing devastating brain cancers.”
Amir Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc
“I look forward to working with Ali to advance that mission and create long-term value for our shareholders.”
Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank and NeOnc Board member
“NeOnc is working to develop treatments for cancers of the brain that remain among the most difficult to treat”
Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank and NeOnc Board member
“I am honored to join the Board and look forward to contributing my experience in governance and international growth as the Company advances its programs.”
CALABASAS, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing therapies for central nervous system cancers, today announced the appointment of Ali Alabedin to its Board of Directors, effective October 9, 2026. Mr. Alabedin is Head of Islamic Banking Group at First Abu Dhabi Bank (FAB), the UAE’s largest bank and a major Gulf banking institution, with AED 1.41 trillion in total assets as of June 30, 2026.
The appointment brings senior banking and governance expertise to NeOnc’s Board as the Company advances its clinical programs and expands its development activities in Abu Dhabi. The Department of Health – Abu Dhabi has granted IND authorization for NEO212, supporting the Company’s plans for Phase 2 development in the UAE, subject to required ethics approvals and other pre-enrollment conditions.
Get started
Create a free account to read the full story.